The Administrative core will be responsible forthe overall management, communication, coordination and supervision of the grant. The Core will coordinate interaction between the 5 Study Sites, the Project P.l.s and Core directors. The Administrative Core will facilitate progress and completion of individual projects. The Core will schedule investigator meetings and conference calls, produce a quarteriy report to keep sites abreast ofthe progress ofthe studies, report to the NIH Steering Committee (and Core personnel will attend Steering Committee meetings), and ultimately assist in manuscript preparation, research reports and correspondence for investigators. The grant requires specimen and clinical data collection at the sites, transmission ofthe specimens to the central labs, and transmission of the clinical data to the multicenter database. The Core will facilitate seamless interaction between sites. Project, and Core personnel. The Core will be responsible for the disbursement of funds and for the preparation of the annual progress reports for the NIH.
Our grant consists of 5 Study Sites, 3 Cores, and 2 Projects. The Administrative Core will facilitate progress toward our goals: to determine if genetic variation is associated with kidney transplant outcome and /or immunosuppressive drug disposition and toxicity. Our findings may lead to the ability to individualize immunosuppressive therapy based on genetics to improve recipient outcome, and may elicit new information on pathways important in the immune response or in immunosuppressive drug efficacy, disposition, and toxicity.
|Julian, B A; Gaston, R S; Brown, W M et al. (2016) Effect of Replacing Race with Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index. Am J Transplant :|
|Oetting, W S; Jacobson, P A; Israni, A K (2016) Validation Is Critical for Genome-Wide Association Study-Based Associations. Am J Transplant :|
|Dorr, Casey R; Freedman, Barry I; Hicks, Pamela J et al. (2016) Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes. PLoS One 11:e0152775|
|Freedman, Barry I; Pastan, Stephen O; Israni, Ajay K et al. (2016) APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation 100:194-202|
|Oetting, W S; Schladt, D P; Guan, W et al. (2016) Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. Am J Transplant 16:574-82|
|Sanghavi, K; Brundage, R C; Miller, M B et al. (2015) Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J :|
|Ong, Song; Mannon, Roslyn B (2015) Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine. Transplant Rev (Orlando) 29:60-7|
|Ma, Jun; Divers, Jasmin; Palmer, Nicholette D et al. (2015) Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation. Kidney Int 88:584-92|
|International Genetics & Translational Research in Transplantation Network (iGeneTRAiN) (2015) Design and Implementation of the International Genetics and Translational Research in Transplantation Network. Transplantation 99:2401-12|
|Freedman, B I; Julian, B A; Pastan, S O et al. (2015) Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant 15:1615-22|
Showing the most recent 10 out of 33 publications